Pre-made Inclacumab benchmark antibody ( Whole mAb, anti-SELP therapeutic antibody, Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Inclacumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-270-1mg	1mg	3090
GMP-Bios-ab-270-10mg	10mg	Inquiry
GMP-Bios-ab-270-100mg	100mg	Inquiry
GMP-Bios-ab-270-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Inclacumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody
INN Name	Inclacumab
Target	SELP
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	Genmab;Roche;Global Blood Therapeutics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders
Development Tech	Medarex UltiMAb Mouse